Company Overview and News

9
CLNE / Clean Energy Fuels Corp. / TOTAL S.A. - SC 13D/A (Activist Investment)

2018-06-14 sec.gov
SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
CLNE

17
CLNE / Clean Energy Fuels Corp. / TOTAL S.A. - SC 13D/A (Activist Investment)

2018-06-14 sec.gov
SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
CLNE

17
CLNE / Clean Energy Fuels Corp. 8-K (Current Report)

2018-06-13 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CLNE

51
Short Sellers Mixed on Solar Stocks, but Are Betting Against Alt Energy

2018-06-12 247wallst
Short interest moves among solar and alternative energy stocks were mixed during the two-week reporting period that ended on May 31. Among the companies we watch, short interest rose on two of three solar stocks and on three out of four alternative energy stocks.
SPWR CLNE FCELB PEIX FSLR CSIQ PLUG FCEL

9
Clean Energy Fuels Hits The Target - Is There More Upside To Come?

2018-06-11 seekingalpha
During the second week of May, CLNE stock hit a new short-term high at $2.36 per share, over 66% higher than the price on March 6...As the chart over the past year shows, the next level of technical resistance now stands at $2.60 per share, the September 14, 2017 high, and then at $3.05 the July 25, 2017 peak and my initial target level for the shares of CLNE.
FP CLNE RNG

31
CLNE / Clean Energy Fuels Corp. SD

2018-05-30 sec.gov
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CLNE

21
Clean Energy (CLNE) Soars: Stock Adds 9.1% in Session

2018-05-30 zacks
Clean Energy Fuels Corp. (CLNE - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 78.3% in the past one-month time frame.
LKSD MARK TXN CLNE UGI LKSD.WI

12
CLNE / Clean Energy Fuels Corp. DEFR14A

2018-05-21 sec.gov
DEFR14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLNE

10
Natural Gas - Is Lower Volatility Here To Stay?

2018-05-21 seekingalpha
Natural gas futures that trade on the New York Mercantile Exchange division of the CME has a long history as one of the most volatile commodities markets. The potential for wide price variance attracts speculators who look to profit from bullish and bearish trends in the energy commodity. Since the introduction of futures on the combustible fossil fuel in 1990, NYMEX natural gas futures traded from lows of $1.
CLNE

9
CLNE / Clean Energy Fuels Corp. / TOTAL S.A. - SC 13D (Activist Investment)

2018-05-18 sec.gov
SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
CLNE

12
CLNE / Clean Energy Fuels Corp. / TOTAL S.A. - SC 13D (Activist Investment)

2018-05-18 sec.gov
SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
CLNE

12
Update On Clean Energy Fuels Corp.

2018-05-15 seekingalpha
On March 6, in an article on Seeking Alpha, I explained that the price of Clean Energy Fuels Corporation (NASDAQ:CLNE) shares had fallen off the side of a cliff and were ripe for a recovery. In that piece, I wrote, "CLNE is a lotto ticket that could pay off, and a 100% move is not out of the question." In a follow up on March 22, I pointed out that insider buying was a positive sign for the stock and put a $3 target on the price of CLNE shares.
FP CLNE TOT

10
Total Investment A Game-Changer For Clean Energy Fuels

2018-05-11 seekingalpha
A surprise announcement from Clean Energy Fuels on Thursday just prior to earnings sent CLNE stock up 12.57%.
CLNE

11
Clean Energy Fuels' (CLNE) CEO Andrew Littlefair on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Greetings and welcome to the Clean Energy Fuels first quarter 2018 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
CLNE RSG WM

14
CLNE / Clean Energy Fuels Corp. 10-Q (Quarterly Report)

2018-05-10 sec.gov
Document Table of Contents
CLNE

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to CLNE / Clean Energy Fuels Corp. on message board site Silicon Investor.

Clean Energy Fuels (CLNE)
CUSIP: 184499101